Viveve Medical Inc (NASDAQ:VIVE) Sellers Strengthened By 5.89% Their Shorts

June 27, 2018 - By Marcos Kline

Viveve Medical Inc (NASDAQ:VIVE) reported an increase of 5.89% in short interest. FINRA published in June VIVE’s total 3.33 million short interest. The up change of 5.89% from 3.14M shares was reported. Viveve Medical Inc (NASDAQ:VIVE) has 281,800 shares average volume. It’ll cost 12 days for VIVE to restore its former position. Viveve Medical Inc float short is 37.34%.

VIVE is touching $2.75 during the last trading session, after decreased 0.72%.Currently Viveve Medical, Inc. is downtrending after 65.48% change in last June 27, 2017. VIVE has also 152,786 shares volume. The stock underperformed the S&P500 by 78.05%.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity.The firm is worth $85.99 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories.Last it reported negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

For more Viveve Medical, Inc. (NASDAQ:VIVE) news announced briefly go to:,,, or The titles are as follows: “5 Stocks Moving In Monday’s After-Hours Session” announced on June 19, 2018, “After-Hours Stock Movers 06/18: (GEVO) (VIVE) (CL) Higher; (PAGS) (TELL) (DEA) Lower (more…)” on June 18, 2018, “Viveve to Present at Jefferies Global Healthcare Conference” with a publish date: May 29, 2018, “Viveve Medical’s CMRF technology shows positive effect in women with SUI; shares up 12% after hours” and the last “Viveve Announces Settlement of Patent Infringement Litigation with Thermi” with publication date: June 04, 2018.

Viveve Medical, Inc. (NASDAQ:VIVE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: